Mortality associated with influenza infections in France before and during the COVID-19 pandemic, and mortality associated with Omicron infections, including mortality for cardiovascular disease and for mental and behavioral disorders

Background There is limited information on mortality associated with influenza and Omicron infections, as infections with those viruses are often not detected, or listed as contributing causes of death.

Methods We applied the previously developed methodology to estimate the contribution of influenza infections to all-cause mortality in France for the 2014-2015 through the 2018-2019 influenza seasons, and the contribution of both SARS-CoV-2 and influenza infections to all-cause mortality between week 33, 2022 through week 12, 2023.

Results For the 2014-2015 through the 2018-2019 seasons, influenza was associated with an average of 15654 (95% CI (13013,18340)) deaths, while between week 33, 2022 through week 12, 2023, we estimated 7851 (5213,10463) influenza-associated deaths and 32607 (20794,44496) SARS-CoV-2 associated deaths. The number of SARS-CoV-2-associated deaths during the Omicron epidemic was significantly higher than the number of deaths with COVID-19 listed on the death certificate or the hospitalization record – for example, between weeks 33-52 in 2022, we estimated 23983 (15307,32620) SARS-CoV-2-associated deaths in France, compared with 12811 deaths with COVID-19 listed on the death certificate, and 8639 in-hospital deaths with COVID-19 during the same period. While we do not have cause-specific mortality data for France, in the US, compared to the SAR-CoV-2 epidemic in the Fall-Winter of 2021-2022, for the first Omicron epidemic wave in 2022 there were significantly higher increases in mortality with cardiovascular disease, as well as with mental/behavioral disorders listed on the death certificate and COVID-19 NOT listed on the death certificate, and smaller increases (compared to the 2020-2021 epidemic) in mortality with either cardiovascular disease or mental/behavioral disorders and COVID-19 listed on the death certificate.

Conclusions The relatively high levels of mortality associated with Omicron infections (including deaths with COVID-19 not listed on the death certificate) suggest the need for wider detection/treatment of Omicron infections (particularly in individuals with underlying health conditions such as mental/behavioral disorders and cardiac disease), as well as for an increase in COVID-19 booster vaccination coverage in different population groups (including non-elderly individuals) to mitigate SARS-CoV-2 transmission in the community. Our results also suggest the need for boosting influenza vaccination coverage in different population groups (including children) in France to mitigate influenza transmission in the community, and for wider testing for influenza infection in respiratory hospitalizations (including pneumonia) in high-risk individuals during influenza seasons in combination with the use of influenza antiviral medications.